Yanping Luo
About Yanping Luo
Yanping Luo serves as the Director of Cell Biology at Kite Pharma and Gilead Sciences, bringing extensive experience in cell biology and immunology. He has held various positions in academia and industry, including roles at the University of Pennsylvania and Tmunity Therapeutics.
Current Role at Kite Pharma
Yanping Luo serves as the Director of Cell Biology at Kite Pharma, a position he has held since February 2023. In this role, he focuses on advancing the company's cell biology initiatives, particularly in the context of developing innovative therapies for cancer treatment. His work is conducted in a hybrid arrangement based in Philadelphia, Pennsylvania.
Previous Experience at Gilead Sciences
Prior to his current role at Kite Pharma, Yanping Luo worked at Gilead Sciences as the Director of Cell Biology. He began this position in 2023, where he contributed to the company's research and development efforts in cell biology. His tenure at Gilead Sciences reflects his ongoing commitment to advancing scientific knowledge in the field.
Academic Background and Research
Yanping Luo has a strong academic foundation in biology and immunology. He earned a Bachelor of Science in Biology from Guangdong Ocean University from 1999 to 2003. He then pursued his Ph.D. in Immunology at the University of Chinese Academy of Sciences, completing his studies from 2003 to 2011. Additionally, he participated in an exchange program at the University of Pennsylvania, where he studied Immunology from 2006 to 2011.
Professional Experience at University of Pennsylvania
Yanping Luo has extensive experience at the University of Pennsylvania, where he held multiple positions. He worked as a Joint PhD student from 2006 to 2010, followed by a role as a Research Specialist from 2010 to 2014. He later served as a Research Scientist at the Center for Cellular Immunotherapies from 2014 to 2017. His time at the University of Pennsylvania contributed significantly to his expertise in cell biology and immunotherapy.
Expertise in Chimeric Antigen Receptors
Yanping Luo possesses specialized expertise in evaluating the function of chimeric antigen receptors in vivo, particularly concerning leukemia and solid tumors. This knowledge is pivotal in his current and previous roles, where he has contributed to the development of targeted therapies aimed at improving patient outcomes in cancer treatment.